Virology & Infectious Diseases RFP Opportunities

Creating-Possible-Fund-HeroBanner
Some content on this site is not intended for people outside of the United States.

RFP Programs

Program Description LOI Due Date
HBV: B-PRO PDF Icon Evaluating the patient experience for those living with chronic hepatitis B and the patient-reported outcomes associated with HBV treatment May 19, 2025
SPEARHEAD 2.0 HDV PDF Icon Addressing HDV linkage to care barriers and understanding optimal testing and diagnosis practices June 6, 2025
GATHER AND LISTEN RFP PDF Icon Long-term outcomes for women with viral hepatitis or primary biliary cholangitis (PBC), integrating HIV and hepatitis care models and addressing social and structural barriers to care. June 20, 2025

.

Gilead will evaluate all Letters of Interest (LOIs) addressing one or more of the following topic areas on a rolling basis until funds are exhausted.

Safety and efficacy of liposomal amphotericin B* alone or in combination with other antifungals

  • Hematologic malignancies or disease
  • Nebulized liposomal amphotericin B therapy
  • Cryptococcal meningitis data, building upon but not replicating the Jarvis et al. NEJM study
  • Outcomes associated with early treatment Intermittent dosing in the prophylaxis setting or as maintenance therapy
  • Mucormycosis
  • Talaromycosis
  • Liposomal amphotericin B in breakthrough invasive fungal infections Intensive Care Unit (ICU) patients
  • Renally-impaired patients
  • Hepatically-impaired patients
  • Post-transplant patients

Antifungal resistance

  • Large multi-center, country-wide or even several country studies (No single center resistance studies)
  • Large studies investigating liposomal amphotericin B in the treatment of C. Auris

Epidemiology of invasive fungal disease

  • Registry data
  • ICU
  • Hematology

Risk evaluation

  • Studies that clarify safety of azoles
  • Renal dysfunction – studies that clarify safety of liposomal amphotericin B, or studies that showcase the benefits of pre-emptive renal safety care in patients treated with liposomal amphotericin B
  • Other special populations, such as post-transplant

*Researchers should consider the local label or indication for liposomal amphotericin B and contact their local Gilead Medical representative for any questions.

Apply for Research Funding

Together, we can generate critical, high-quality research that has an impact on clinical decision-making and patients’ lives.

Apply Now